Explainer: RSV may not quite have the name recognition that influenza and Covid do, but it's actually causing more winter ...

Final trial results add to evidence supporting use in tots who remain at increased risk ...

International evidence has shown immunisation programmes reduces hospitalisations from respiratory syncytial virus by up to ...

Viral infections that attack the lungs are among the leading reasons infants are hospitalized. A new treatment may offer protection against these infections that is as effective and safe as existing ...

The FDA has called out Sanofi’s promotion of respiratory syncytial virus (RSV) antibody Beyfortus in a new untitled letter, taking issue with the company’s characterization of the med as a general | ...

One immunization may protect newborns against two serious illnesses, according to a new study from France.

A U.K. marketing watchdog has reprimanded Sanofi for using “a highly misleading interpretation of data” to make disparaging claims about Pfizer’s respiratory syncytial virus (RSV) vaccine.

Up to two thousand Kiwi under-fives are hospitalised with the virus each year, particularly those under six months. Co-author Professor Cass Byrnes says investing in infant and maternal immunisations ...

Australians have been warned as Respiratory Syncytial Virus (RSV) cases are expected to surge in the coming weeks.

The supply crunch is expected to last until at least 2028.

Australia’s immunisation policy to protect babies against severe disease from the viral infection RSV may be leaving many ...